{"id":74993,"date":"2026-08-17T15:16:12","date_gmt":"2026-08-17T07:16:12","guid":{"rendered":"https:\/\/flcube.com\/?p=74993"},"modified":"2026-08-17T15:16:14","modified_gmt":"2026-08-17T07:16:14","slug":"asieris-pharmaceuticals-wins-fda-clearance-for-apl-2501-an-anti-cldn6-9-adc-in-advanced-solid-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=74993","title":{"rendered":"Asieris Pharmaceuticals Wins FDA Clearance for APL\u20112501, an Anti\u2011CLDN6\/9 ADC in Advanced Solid Tumors"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Jiangsu Asieris Pharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/688176:SHA\">SHA: 688176<\/a>) announced that its independently developed <strong>APL\u20112501<\/strong> has received <strong>US Food and Drug Administration (FDA) approval to conduct clinical trials<\/strong> for the treatment of <strong>advanced solid tumors<\/strong>. The clearance marks the company&#8217;s first US clinical entry for its proprietary CLDN6\/9\u2011targeting antibody\u2011drug conjugate.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>FDA (US)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial approval (IND)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>APL\u20112501 (anti\u2011CLDN6\/9 antibody\u2011drug conjugate)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Advanced solid tumors, including ovarian, non\u2011small cell lung, endometrial, and gastric cancers<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>17 Aug 2026<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>Initiation of clinical studies in advanced solid tumors in the US<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>APL\u20112501<\/strong>, a proprietary <strong>anti\u2011CLDN6\/9 antibody\u2011drug conjugate (ADC)<\/strong> independently developed by <strong>Asieris Pharmaceuticals<\/strong><\/li>\n\n\n\n<li><strong>Payload:<\/strong> <strong>Topoisomerase inhibitor<\/strong> warhead<\/li>\n\n\n\n<li><strong>Linker Technology:<\/strong> Proprietary <strong>hydrophilic linker<\/strong> supporting <strong>homogeneous DAR8 conjugation<\/strong>, delivering excellent stability and a broader therapeutic window<\/li>\n\n\n\n<li><strong>Antibody:<\/strong> High\u2011affinity <strong>CLDN6\/9 monoclonal antibody<\/strong> for selective tumor targeting<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-differentiation-vs-existing-adcs\" class=\"wp-block-heading\">Differentiation vs. Existing ADCs<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Advantage (APL\u20112501)<\/th><\/tr><\/thead><tbody><tr><td><strong>Target Profile<\/strong><\/td><td>CLDN6\/9 expression differs from existing ADC\u2011targeting antigens<\/td><\/tr><tr><td><strong>Conjugation<\/strong><\/td><td>Homogeneous DAR8 for consistent drug\u2011to\u2011antibody ratio<\/td><\/tr><tr><td><strong>Stability<\/strong><\/td><td>Excellent stability via hydrophilic linker design<\/td><\/tr><tr><td><strong>Therapeutic Window<\/strong><\/td><td>Broader than conventional ADC architectures<\/td><\/tr><tr><td><strong>Patient Benefit<\/strong><\/td><td>Potential clinical benefit for patients who do not respond to current ADC therapies<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The product&#8217;s target expression profile differs from existing ADC\u2011targeting antigens, offering potential clinical benefits for patients who do not respond to current ADC therapies \u2014 a growing need as resistance to established ADC targets such as HER2 and TROP2 emerges.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Novel Target Opportunity:<\/strong> CLDN6\/9 represents an emerging ADC target distinct from crowded antigens, positioning <strong>APL\u20112501<\/strong> to address patients who progress on currently approved or late\u2011stage ADC therapies.<\/li>\n\n\n\n<li><strong>Broad Tumor Coverage:<\/strong> The anticipated indication set \u2014 <strong>ovarian cancer, non\u2011small cell lung cancer, endometrial cancer, and gastric cancer<\/strong> \u2014 spans multiple high\u2011incidence malignancies, supporting a wide development opportunity.<\/li>\n\n\n\n<li><strong>Engineering Differentiation:<\/strong> Homogeneous DAR8 conjugation with a hydrophilic linker addresses key ADC limitations around stability and toxicity, potentially translating into a wider therapeutic window in the clinic.<\/li>\n\n\n\n<li><strong>Global Footprint:<\/strong> FDA clearance validates <strong>Asieris Pharmaceuticals&#8217;<\/strong> ADC platform and establishes a US clinical pathway, complementing the company&#8217;s domestic development strategy and enhancing partnership leverage in the competitive ADC licensing market.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical trial conduct, efficacy outcomes, and commercial potential for APL\u20112501. Actual results may differ due to risks including Phase I safety and efficacy data, regulatory decisions, and competitive dynamics in the ADC market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/688176_20260814_VL7M.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688176_20260814_VL7M.\"><\/object><a id=\"wp-block-file--media-01b53a64-024a-495e-b797-cf0e54c532ea\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/688176_20260814_VL7M.pdf\">688176_20260814_VL7M<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/688176_20260814_VL7M.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-01b53a64-024a-495e-b797-cf0e54c532ea\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Asieris Pharmaceuticals Co., Ltd. (SHA: 688176) announced that its independently developed APL\u20112501 has received&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[35,316,62,1127],"class_list":["post-74993","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-asieris-pharmaceuticals","tag-clinical-trial-approval-initiation","tag-sha-688176"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Asieris Pharmaceuticals Wins FDA Clearance for APL\u20112501, an Anti\u2011CLDN6\/9 ADC in Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Asieris Pharmaceuticals Co., Ltd. (SHA: 688176) announced that its independently developed APL\u20112501 has received US Food and Drug Administration (FDA) approval to conduct clinical trials for the treatment of advanced solid tumors. The clearance marks the company&#039;s first US clinical entry for its proprietary CLDN6\/9\u2011targeting antibody\u2011drug conjugate.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=74993\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Asieris Pharmaceuticals Wins FDA Clearance for APL\u20112501, an Anti\u2011CLDN6\/9 ADC in Advanced Solid Tumors\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Asieris Pharmaceuticals Co., Ltd. (SHA: 688176) announced that its independently developed APL\u20112501 has received US Food and Drug Administration (FDA) approval to conduct clinical trials for the treatment of advanced solid tumors. The clearance marks the company&#039;s first US clinical entry for its proprietary CLDN6\/9\u2011targeting antibody\u2011drug conjugate.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=74993\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-17T07:16:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-17T07:16:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=74993#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=74993\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Asieris Pharmaceuticals Wins FDA Clearance for APL\u20112501, an Anti\u2011CLDN6\\\/9 ADC in Advanced Solid Tumors\",\"datePublished\":\"2026-08-17T07:16:12+00:00\",\"dateModified\":\"2026-08-17T07:16:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=74993\"},\"wordCount\":432,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Asieris Pharmaceuticals\",\"Clinical trial approval \\\/ initiation\",\"SHA: 688176\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=74993#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=74993\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=74993\",\"name\":\"Asieris Pharmaceuticals Wins FDA Clearance for APL\u20112501, an Anti\u2011CLDN6\\\/9 ADC in Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-17T07:16:12+00:00\",\"dateModified\":\"2026-08-17T07:16:14+00:00\",\"description\":\"Jiangsu Asieris Pharmaceuticals Co., Ltd. (SHA: 688176) announced that its independently developed APL\u20112501 has received US Food and Drug Administration (FDA) approval to conduct clinical trials for the treatment of advanced solid tumors. The clearance marks the company's first US clinical entry for its proprietary CLDN6\\\/9\u2011targeting antibody\u2011drug conjugate.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=74993#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=74993\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=74993#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Asieris Pharmaceuticals Wins FDA Clearance for APL\u20112501, an Anti\u2011CLDN6\\\/9 ADC in Advanced Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Asieris Pharmaceuticals Wins FDA Clearance for APL\u20112501, an Anti\u2011CLDN6\/9 ADC in Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Asieris Pharmaceuticals Co., Ltd. (SHA: 688176) announced that its independently developed APL\u20112501 has received US Food and Drug Administration (FDA) approval to conduct clinical trials for the treatment of advanced solid tumors. The clearance marks the company's first US clinical entry for its proprietary CLDN6\/9\u2011targeting antibody\u2011drug conjugate.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=74993","og_locale":"en_US","og_type":"article","og_title":"Asieris Pharmaceuticals Wins FDA Clearance for APL\u20112501, an Anti\u2011CLDN6\/9 ADC in Advanced Solid Tumors","og_description":"Jiangsu Asieris Pharmaceuticals Co., Ltd. (SHA: 688176) announced that its independently developed APL\u20112501 has received US Food and Drug Administration (FDA) approval to conduct clinical trials for the treatment of advanced solid tumors. The clearance marks the company's first US clinical entry for its proprietary CLDN6\/9\u2011targeting antibody\u2011drug conjugate.","og_url":"https:\/\/flcube.com\/?p=74993","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-17T07:16:12+00:00","article_modified_time":"2026-08-17T07:16:14+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=74993#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=74993"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Asieris Pharmaceuticals Wins FDA Clearance for APL\u20112501, an Anti\u2011CLDN6\/9 ADC in Advanced Solid Tumors","datePublished":"2026-08-17T07:16:12+00:00","dateModified":"2026-08-17T07:16:14+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=74993"},"wordCount":432,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Asieris Pharmaceuticals","Clinical trial approval \/ initiation","SHA: 688176"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=74993#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=74993","url":"https:\/\/flcube.com\/?p=74993","name":"Asieris Pharmaceuticals Wins FDA Clearance for APL\u20112501, an Anti\u2011CLDN6\/9 ADC in Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-17T07:16:12+00:00","dateModified":"2026-08-17T07:16:14+00:00","description":"Jiangsu Asieris Pharmaceuticals Co., Ltd. (SHA: 688176) announced that its independently developed APL\u20112501 has received US Food and Drug Administration (FDA) approval to conduct clinical trials for the treatment of advanced solid tumors. The clearance marks the company's first US clinical entry for its proprietary CLDN6\/9\u2011targeting antibody\u2011drug conjugate.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=74993#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=74993"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=74993#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Asieris Pharmaceuticals Wins FDA Clearance for APL\u20112501, an Anti\u2011CLDN6\/9 ADC in Advanced Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/74993","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=74993"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/74993\/revisions"}],"predecessor-version":[{"id":75001,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/74993\/revisions\/75001"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=74993"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=74993"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=74993"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}